CAMBRIDGE, Mass., October 31, 2022 – The nomination process has officially commenced for the inaugural Richard N. Merkin Prize in Biomedical Technology, designed to honor innovative technologies that significantly contribute to human health improvement.
This annual prize will spotlight a groundbreaking technology and acknowledge up to four key contributors, distributing a total cash award of $400,000 among the winners. The selected technology must demonstrate a tangible impact on health by advancing the treatment, diagnosis, or prevention of diseases.

The Merkin Prize is overseen by the Broad Institute of MIT and Harvard, renowned as one of the world’s foremost biomedical research institutions. “The Merkin Prize will underscore the inventors behind crucial medical technologies and illustrate the transformative effect of their work on healthcare,” stated Harold Varmus, chair of the selection committee and Nobel Prize laureate for his research on cancer origins.

Eligibility for the Merkin Prize extends to all living researchers globally, spanning any discipline within academia, the commercial sector, or government. While anyone can submit a nomination, self-nominations are prohibited. All nominations must be received by January 23, 2023.

For further details, nomination guidelines, and forms, visit merkinprize.org.

About the Merkin Family Foundation
The Merkin Family Foundation was established by Richard Merkin, MD, a prominent healthcare executive. Dr. Merkin is the founder and CEO of Heritage Provider Network, Inc. (HPN), the largest physician-owned managed care organization in the United States. HPN is dedicated to enhancing value-based healthcare delivery, operating in New York, California, Arizona, and Colorado, and serving over one million patients with a focus on quality and cost-effective healthcare.

About the Broad Institute of MIT and Harvard
Founded in 2004, the Broad Institute aims to empower innovative scientists to transform medicine. It strives to elucidate the molecular components of life, uncover the underlying causes of significant human diseases, and develop effective diagnostic and therapeutic approaches. The institute promotes open dissemination of discoveries and tools across the global scientific community, collaborating with over 100 private and public institutions across 40 countries.